Eris Lifesciences Ltd has released its investor presentation detailing a 12% organic revenue growth in Q3 FY25 and a 39% EBITDA margin, showing positive financial momentum. The company also noted a rise in EBITDA margin by 237 bps year-on-year.
AI Assistant
ERIS Lifesciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.